Phaseline

Companies › Materia Medica Holding

Materia Medica Holding: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 5 Phase 3; Infectious disease, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Raphamin (MMH-407)–Phase 3Cystitis Chronic; Rhinosinusitis; Acute Respiratory Viral Infection; BronchitisDec 2026
Rengalin
unclear - proprietary combination medication
–Phase 3CoughDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06284265Raphamin (MMH-407)Phase 3Cystitis ChronicInfectious diseaseDec 2026
NCT06901297Raphamin (MMH-407)Phase 3RhinosinusitisRespiratoryDec 2027
NCT06715891Raphamin (MMH-407)Phase 3Acute Respiratory Viral InfectionInfectious diseaseDec 2027
NCT07650227Raphamin (MMH-407)Phase 3BronchitisRespiratoryDec 2028
NCT07171099RengalinPhase 3CoughInfectious diseaseDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Laboratorio Farmaceutico SIT srl Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Jiangxi Qingfeng Pharmaceutical Zero Point Five Therapeutics MicuRx

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.